Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: ALNYLAM PHARMACEUTICALS, INC.
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: ALNYLAM PHARMACEUTICALS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALNYLAM PHARMACEUTICALS, INC. via ALNYLAM PHARMACEUTICALS, INC.
2026 · third_quarter · Q3
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Issues relating to supply chain tariffs
Source: Senate LDA
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Joe Fiandra Access to Home Infusion Act of 2025
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: ALNYLAM PHARMACEUTICALS, INC.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Joe Fiandra Access to Home Infusion Act of 2025
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: ALNYLAM PHARMACEUTICALS, INC.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via ALNYLAM PHARMACEUTICALS, INC.
2026 · second_quarter · Q2
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Issues relating to supply chain tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE